This NKp46/Fc/EGFR TriKE shows remarkable advantages in augmenting NK infiltration in tumor tissue and promoting their anti-cancer efficacy over anti-EGFR mAb therapies such as cetuximab. This evidence concerns the gene EGFR and cancer.